Microbion Corporation

Microbion is a clinical-stage pharmaceutical company developing a novel class of compounds for the treatment of difficult-to-treat infections, including chronic infections and antibiotic-resistant infections. Microbion is dedicated to developing best-in-class, novel medicines that uniquely address key unmet medical needs and thereby provide physicians with durable, breakthrough options to improve and extend the lives of patients. Pravibismane, our lead therapeutic candidate, is the first in a new class of anti-infective drugs with broad-spectrum activity and a novel mechanism of action that halts microbial cellular metabolism. Pravibismane has an unprecedented ability to prevent and eradicate biofilms that contribute to chronic infection and facilitate antibiotic-resistance.